Mydecine Innovations Group Inc. (MYCO.CN)
- Previous Close
0.0100 - Open
0.0050 - Bid --
- Ask --
- Day's Range
0.0050 - 0.0050 - 52 Week Range
0.0050 - 0.0200 - Volume
4,700 - Avg. Volume
52,660 - Market Cap (intraday)
308,777 - Beta (5Y Monthly) 3.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date Jun 30, 2025 - Jul 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005. The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
www.mydecine.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MYCO.CN
View MorePerformance Overview: MYCO.CN
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYCO.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYCO.CN
View MoreValuation Measures
Market Cap
617.55k
Enterprise Value
7.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-188.53%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.46M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
60.17k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
4.03M